Bedfont® now focuses on supporting clinical research, debuting at the 9th annual Outsourcing in Clinical Trials DACH in Basel.

Bedfont® Scientific Limited, a world leader in breath analysis with 50 years of experience manufacturing medical devices, has quietly supported respiratory research around the world and is set to make its debut at its first clinical trial-focused event in November, taking the next step toward a dedicated focus on supporting clinical trials and clinical research teams, marking the beginning of a new chapter at Bedfont®.

Outsourcing in Clinical Trials (OCT) DACH is an annual conference that brings together professionals involved in the planning, management and outsourcing of clinical trials across Germany, Austria and Switzerland. As Bedfont® expands its focus on supporting clinical trials, attending OCT DACH is the perfect opportunity to engage directly with the professionals shaping the future of clinical research.

Bedfont® Team - Respiratory clinical research

“The future of respiratory medicine depends on robust clinical research. As biomarkers continue to play an increasingly important role in clinical trials, researchers need partners they can rely on for both scientific expertise and dependable technology.” Says Jason Smith, CEO at Bedfont®, “Building on our experience in respiratory diagnostics and the established use of NObreath® in clinical studies, we are excited to strengthen our support for the clinical research community and look forward to building relationships with the organisations leading respiratory studies at OCT DACH in November.”


The NObreath® FeNO device has been aiding asthma diagnosis and management for over 15 years. Designed for reliability, NObreath® provides accurate, repeatable FeNO measurements for long-term studies, making it the perfect choice for clinical trials. You can find the Bedfont® team at stand 10b for live demonstrations of NObreath® and to see how straightforward it is to incorporate FeNO testing into clinical trial protocols and patient visits.


To learn more about NObreath® and Bedfont’s attendance at this year’s conference, visit the website here.

Asthma is a chronic lung condition affecting approximately 339.4 million people worldwide1, and when uncontrolled, it can be quite debilitating in everyday life. Despite modern-day medicine and the availability of effective treatments, approximately 39% of people with asthma remain uncontrolled1.

What do we mean by asthma control?

Asthma can cause various symptoms such as2:

  • Wheezing,
  • Coughing,
  • Shortness of breath,
  • Tight chest.

Asthma control can be measured by symptom frequency, night waking, reliever use, and activity limitations. Poor asthma control can be identified by increased symptoms, and controlled asthma can be recognised by minimal symptoms. Asthma is variable, so symptoms and control can change over time. Because of this, regular asthma reviews are important, even when patients feel fine. Reviews can help to evaluate the risk of future exacerbations and monitor treatment effectiveness.

Asthma symptoms, asthma control

What can good asthma control look like?

People with good asthma control should be able to carry out day-to-day activities with little to no limitations. However, it seems that people living with asthma have become accustomed to expecting symptoms daily and believe this to be normal. A European study found that out of 8,000 people, 80% considered their asthma to be controlled, when it was found that 45.1% had uncontrolled asthma3.

When asthma is under control, people should4:

  • Have few to no daytime symptoms,
  • Have reduced nighttime waking due to asthma,
  • Have less reliance on reliever medication,
  • Participate in exercise and sports.

More importantly, those with good asthma control should experience fewer exacerbations and fewer unscheduled healthcare appointments. Uncontrolled asthma can place a significant burden on healthcare systems; in 2023, the total direct cost to the NHS was believed to be over £1.5 billion5, emphasising the need for better asthma care.

Why symptoms don’t always tell the full story.

Airway Inflammation Infographic

In most people with asthma, inflammation can drive symptoms, but because airway inflammation is not visible, it is often overlooked. If a patient attends a routine asthma review and reports feeling fine, with little to no symptoms, airway inflammation can still be present, increasing the risk of future exacerbations. This demonstrates the need for objective testing in routine care to assess what cannot be seen: airway inflammation.

It is important to build a full picture of what’s happening in the airways instead of just asking about symptoms. This is where Fractional exhaled Nitric Oxide (FeNO) testing is vital to the asthma pathway.

What is FeNO testing6?

FeNO is a non-invasive biomarker associated with type 2 airway inflammation; it measures nitric oxide (NO) in exhaled breath. When inflammation is present in the airways, more NO is produced and can be measured in a person’s breath, helping to assess the level of airway inflammation. FeNO testing provides the missing piece of the puzzle as it can:

  • Support an asthma diagnosis,
  • Help clinicians make informed treatment decisions,
  • Identify poor adherence or inhaler technique,
  • Open up more informed conversations between patients and healthcare professionals.

Asthma is a variable condition, with symptoms, triggers and levels of airway inflammation potentially changing over time. Incorporating FeNO testing into routine asthma management can provide healthcare professionals with an objective measure of type 2 airway inflammation, helping them monitor changes over time and build a more complete picture of a patient’s asthma control.

As technology and understanding of FeNO have evolved, its role in asthma care has become increasingly recognised. In the UK, the 2024 joint asthma guideline from the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN) incorporated FeNO testing into recommendations for the diagnosis and ongoing management of asthma7.

FeNO testing with the NObreath®.

The NObreath® is an FeNO device that has supported asthma diagnosis and management for over 15 years. Designed with the patient in mind, it provides adult and child test modes, making it suitable for most ages. Its compact, portable design makes it ideal for busy primary and secondary care settings, delivering accurate, reliable FeNO results trusted by healthcare professionals worldwide.

Good control is personal.

Everyone’s normal is different, so good asthma control isn’t about achieving a number; it should mean positive outcomes for the individual, which can translate to:

  • Sleeping through the night,
  • Exercising,
  • Not missing work or school because of symptoms,
  • Playing sport.

Good asthma control is about understanding symptoms and reducing future risk. Instead of focusing only on symptoms, consider inflammation. By providing an objective measurement of type 2 airway inflammation, FeNO testing adds the missing piece to the puzzle, helping healthcare professionals make more informed decisions and provide more personalised asthma care, ultimately improving patient outcomes.

To learn more about the role of FeNO testing in asthma management, read our blog here. For more information on FeNO testing with the NObreath®, visit the website here.

References

  1. Busse WW, Kraft M. Current unmet needs and potential solutions to uncontrolled asthma. European Respiratory Review [Internet]. 2022 Mar 31 [cited 2026 Sept 7];31(163). Available from: https://err.ersjournals.com/content/31/163/210176.long
  2. NHS. Asthma [Internet]. NHS. 2021 [cited 2026 Sept 7]. Available from: https://www.nhs.uk/conditions/asthma/
  3. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. npj Primary Care Respiratory Medicine [Internet]. 2014 June 12 [cited 2026 Sept 7];24(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373302/
  4. Asthma Zones: Signs of Controlled and Uncontrolled Asthma ǀ AAFA.org [Internet]. Asthma and Allergy Foundation of America. 2026 [cited 2026 Sept 7]. Available from: https://aafa.org/asthma/asthma-symptoms/asthma-control/
  5. Asthma + Lung UK [Internet]. 2023. [Cited September 2026]. Available from: https://www.asthmaandlung.org.uk/investing-breath-measuring-economic-cost-asthma-copd-uk-identifying-ways-reduce-it-through-better
  6. Asthma + Lung UK. FeNO test | Asthma + Lung UK [Internet]. www.asthmaandlung.org.uk. 2022 [cited 2026 Sept 7]. Available from: https://www.asthmaandlung.org.uk/symptoms-tests-treatments/tests/feno-test
  7. National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024 [cited 2026 Sept 7]. Available from: https://www.nice.org.uk/guidance/NG245

Showcasing the NObreath® and Smokerlyzer® range while connecting with research teams and global distribution partners at Europe’s leading respiratory congress.

Bedfont® Scientific Limited, a world leader in breath analysis, is excited to be attending this year’s European Respiratory Society (ERS) Congress in Barcelona. With over 50 years of experience in the design and manufacture of medical breath analysis devices, Bedfont® looks to connect with professionals in healthcare and clinical research to share its innovative Fractional exhaled Nitric Oxide (FeNO) and carbon monoxide (CO) monitoring technology.

The ERS Congress is the world’s largest international meeting dedicated to respiratory medicine, bringing together approximately 20,000 clinicians, researchers, healthcare professionals and industry leaders from across the world. This year’s congress takes place in Barcelona from the 5th to the 9th of September, providing a platform for sharing the latest scientific advances, promoting collaboration and driving innovation in respiratory care.

This year’s theme is “United for better breathing: partnership between patients, clinicians and researchers.” With Bedfont® looking to strengthen its commitment to respiratory clinical research, ERS provides the perfect platform to connect with industry professionals and showcase its innovations.

Jason Smith, CEO at Bedfont®, comments, “ERS Congress is one of the most important events in the respiratory calendar, bringing together the very people driving innovation in respiratory medicine. We’re excited to return to Barcelona to showcase our NObreath® FeNO device and Smokerlyzer® range, while strengthening relationships with our distributor network and connecting with research teams and healthcare professionals. As Bedfont® continues to expand its presence in medical research, we’re looking forward to discussing how our trusted respiratory monitoring solutions can further support studies and ultimately improve patient care around the world.”

The Bedfont® team will be at Stand R.19 from the 6th to the 9th of September, where visitors can explore the NObreath® and Smokerlyzer® devices and meet the experts behind them. Joining the team is renowned respiratory nurse and clinical leader, Carol Stonham MBE, who will be on the stand to share her expertise and provide valuable clinical insight into the role of FeNO testing in respiratory care. Carol will be available alongside Bedfont’s Clinical Research Partnerships Manager, Hannah Vince-Drew, to answer questions and discuss the application of FeNO testing in both clinical practice and clinical research.

To learn more, visit the website here.

NObreath® and Smokerlyzer® at ERS

Over 1,200 NObreath® FeNO devices sold since the 2024 UK guideline update.

Bedfont® Scientific Limited, an innovative leader in breath analysis and Fractional exhaled Nitric Oxide (FeNO) testing for asthma care with the NObreath®, welcomes the news that over 1 million people with asthma are now using combination inhalers1 following the joint 2024 asthma guidelines from the National Institute for Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN)2. This milestone marks a significant shift in asthma management in the UK, with NObreath® sales exceeding 1,240 units since the update.

Personalised Asthma Care

The well-known blue reliever inhaler helps control symptoms but doesn’t address the underlying airway inflammation, the key driver of asthma. Airway inflammation cannot be seen or felt, so whilst patients may not be experiencing any symptoms, the inflammation could be building below the surface, leading to an exacerbation or asthma attack. The NObreath® FeNO device can quickly measure airway inflammation, giving clinicians valuable objective insight enabling them to tailor treatment effectively.

Switching patients to combination inhalers ensures not only symptom relief but also inflammation control. The updated guideline reflects a growing emphasis on prevention-focused asthma care, including earlier anti-inflammatory treatment and reduced reliance on symptom relief alone.

“Seeing more than 1 million people now using combination inhalers marks a significant milestone in the evolution of asthma care. It reflects a growing emphasis on prevention-focused asthma care, including earlier anti-inflammatory treatment and reduced reliance on symptom relief alone. At Bedfont®, we’re proud that FeNO testing is helping support this shift towards more proactive, personalised care. Through the NObreath®, we are helping clinicians gain objective insight into airway inflammation, supporting better-informed decisions and improved long-term outcomes. Everyone deserves access to better asthma care, empowering them to live healthier lives with greater confidence and control.” Said Jason Smith, CEO at Bedfont®.

Bedfont® works closely with its UK distributor, Intermedical UK, to expand access to FeNO testing nationwide. Intermedical launched its NObreath® 3000 campaign last year, signifying a major milestone of 3,000 NObreath® sales in the UK. It also reported growing sales following the guideline update, with over 1,240 devices sold since November 2024 alone, demonstrating the impact of national guidance on asthma care.

A FeNO test with the NObreath® can assess inflammation by measuring nitric oxide (NO) levels in exhaled breath, a biomarker of airway inflammation. The test is quick, easy, and non-invasive, supporting clinicians’ decision-making and treatment plans aligned with evolving guidelines. This milestone reflects a broader shift in asthma care towards precision medicine, biomarker-driven approaches, and more personalised management, all aimed at improving patient outcomes worldwide.

The NObreath® FeNO device has been improving asthma care for over 15 years. To learn more, please visit the website here.

References

  1. “I no longer feel asthmatic”: more than a million people now using new style inhalers [Internet]. NICE website: The National Institute for Health and Care Excellence. NICE; 2026 [cited 2026 May 6]. Available from: https://www.nice.org.uk/news/articles/-i-no-longer-feel-asthmatic-more-than-a-million-people-now-using-new-style-inhalers?
  2. National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024. Available from: https://www.nice.org.uk/guidance/NG245

Asthma is a chronic disease that affects millions worldwide, with many dying from the condition every year1. Asthma care has evolved over the years, but despite the advances, objectively assessing airway inflammation, the key driver of asthma, remains challenging in routine clinical practice.

Historically, asthma management has relied heavily on symptom reporting, but symptoms alone are unreliable indicators of airway inflammation. Inflammation in the airways cannot be seen, and whilst patients may appear clinically stable, airway inflammation may be present, necessitating the use of objective, measurable biomarkers.

FeNO – A non-invasive biomarker technology

Airway inflammation is associated with elevated levels of nitric oxide (NO) in exhaled breath, providing a measurable biomarker of eosinophilic inflammation known as Fractional exhaled Nitric Oxide (FeNO). Using a FeNO device, clinicians can rapidly assess airway inflammation through a non-invasive test that delivers real-time results to support asthma diagnosis, monitoring, and treatment optimisation.

Evolution of FeNO Testing

The evolution of FeNO technology

In the 1990s, researchers found that FeNO served as a non-invasive biomarker of airway inflammation and used chemiluminescence technology to measure it, detecting NO through light emitted during a chemical reaction. This method provided high sensitivity and accuracy but proved very costly due to the need for regular maintenance and calibration, limited accessibility, and the specialist training required to operate it. It was clear that early FeNO technology demonstrated clinical value but lacked scalability.

In recent years, this has advanced to electrochemical sensor technology, enabling a new generation of portable FeNO devices, including the NObreath®, whilst still matching the gold-standard chemiluminescence technology.

Modern FeNO devices using electrochemical sensors have decentralised diagnostics, providing a portable respiratory diagnostic option which is easy to integrate into point-of-care workflows. The devices are easy to use and no longer require specialist training, making them a more cost-effective option in respiratory diagnostics.

How point-of-care FeNO testing changes clinical practice

Thanks to continuous innovation, FeNO devices are now accessible at the point of care, enabling faster clinical decision-making, improved monitoring capabilities, and more personalised asthma management. This evolution reflects a broader shift toward decentralised, non-invasive diagnostic technologies designed to support earlier detection and more proactive respiratory care.

FeNO testing – Ease of use

Recent developments in FeNO devices have focused on usability, workflow efficiency, and accessibility. For example, the NObreath®, now in its 2nd generation, is a portable FeNO device which pioneered the exhalation-only manoeuvre. Helping to improve asthma care for over 15 years, the device is suitable for both adults and children, the test is easy to complete and provides a flow incentive to ensure a flow rate of 50 ml/s, yielding an accurate result. Providing instant results, FeNO testing supports efficient point-of-care workflows and faster clinical decision-making.

The future of respiratory diagnostics

The inclusion of FeNO testing in clinical guidelines has increased throughout the years, with the 2024 UK guidance from the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN) recommending FeNO as a first-line test to aid asthma diagnosis and management2.

This marks a major shift in asthma care, with a growing emphasis on biomarker-led approaches and more personalised treatment strategies to improve patient outcomes. As respiratory diagnostics become increasingly accessible beyond hospitals and specialist centres, more patients can benefit from advanced technologies through primary care, community clinics, and outpatient respiratory services. Reflecting this trend, Intermedical UK, the exclusive UK distributor of the NObreath® FeNO device, has now installed more than 3,000 devices across the UK, including over 1,200 since the 2024 guideline update, highlighting the rapid adoption of FeNO testing in routine clinical practice.

FeNO testing offers a non-invasive option to aid diagnosis and monitoring of asthma, making biomarker testing more accessible and decentralising respiratory monitoring. Continued innovation in this technology may even expand to home monitoring in the future.

NObreath® Evolution of FeNO Testing

References

  1. World Health Organization. Asthma [Internet]. World Health Organization. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma
  2. National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024. Available from: https://www.nice.org.uk/guidance/NG245

Written by Carol Stonham MBE

Carol Stonham MBE - Love Your Lungs Week

This article reflects the opinions of a healthcare professional. The views expressed are their own. The intended use for the NObreath® is as follows:

The 2nd generation NObreath® is a breath nitric oxide (NO) test system intended to measure fractional exhaled nitric oxide (FeNO) in parts per billion (ppb) in exhaled breath.

FeNO measurement is taken to evaluate airway inflammation and should be used in conjunction with other clinical and laboratory evaluations where appropriate when making a diagnosis or treatment plan. The measurements are intended for interpretation by healthcare professionals and for us in a healthcare environment, where paediatric and adult patients will complete measurements under supervision.

Love Your Lungs Week and Asthma

For many people lungs don’t really feature in their daily self-awareness despite the vital work they do. They are there in the background doing their job. For many people Love your Lungs week might just make them think about what a good job their lungs are doing and maybe look for ways of encouraging them to stay healthy – avoiding pollution, not smoking or vaping and getting regular exercise in for example.

For those people with asthma Love Your Lungs week might have a different emphasis. Asthma symptoms, whether minor or more dramatic, will certainly make a person aware of their breathing. Good asthma care can help to keep the symptoms under control and avoid bouts of acute symptoms.

Good asthma care starts with an accurate diagnosis. Historically an asthma diagnosis was made on assessment of symptoms, perhaps some lung function testing, and response to treatment. Evidence shows us we sometimes got it wrong using this approach 1. The current joint UK guidelines from British Thoracic Society (BTS), Scottish Intercollegiate Network (SIGN) and National Institute for Health and Care Excellence (NICE)2 have moved to basing a diagnosis of asthma on assessment of symptoms and history that is supported by objective testing. Fractional exhaled nitric oxide (FeNO) is the first recommended test based on clinical accuracy and cost effectiveness. A raised FeNO is an indicator of eosinophilic airway inflammation which is commonly seen in most types of asthma when it is not adequately treated with inhaled corticosteroids (ICS).

Love Your Lungs Week

Once an accurate diagnosis has been made the person being diagnosed needs to understand what asthma is, what is happening in their lungs, and how their treatment works. There are no agreed education sessions for people newly diagnosed with asthma as there are for those with diabetes.

As asthma is a variable condition, understanding these features support the person to adjust medication to control symptoms and self-manage their condition. Healthcare input is minimal in someone with asthma – an annual review is usually the only planned touch point; others tend to be when the symptoms are poorly controlled. Most healthcare professionals will use a diagram or airway model to explain asthma but the addition of FeNO is a useful tool to demonstrate inflammation especially in the symptomatic person. It helps both practitioner and patient to understand what is happening in the lungs – a measured objective marker demonstrating inflammation.

Why Objective Assessment Remains Important

Many people with a long-term health condition will become so used to the symptoms they experience and the regular use of treatment4. This is seen in some people with asthma – they accept that they have asthma therefore they accept a wheeze or cough4, they stop taking regular ICS treatment and instead rely on a rescue inhaler to treat symptoms as they arise4, or they might continue treatment but fall into bad habits and use their inhaler incorrectly5. In all of these cases measuring FeNO is helpful to assess the underlying airway inflammation, to demonstrate suboptimal control of airway inflammation, and to base ongoing treatment decisions which may require a change of medication, a change of inhaler device or commonly, simply a reminder that asthma treatment needs to be taken regularly with good technique.

The NObreath® FeNO Device

Love Your Lungs Week

FeNO testing with the NObreath® is a quick and easy non-invasive way to objectively measure airway inflammation. With adult and child test modes, the NObreath® is suitable for all settings thanks to its accuracy and portability. Featuring an exhalation-only manoeuvre, the test is easy to do and can help to improve asthma care, allowing healthcare professionals to tailor asthma treatment effectively.

Love Your Lungs for those with asthma should focus on getting the treatment right and taking it effectively and regularly so that the lungs can get on doing their job without reminding the person they have asthma at all. Of course, that will also include the general measures that everyone else will be considering – avoiding pollution, avoiding smoking and vaping, and getting regular exercise in, but good asthma care will support activity without a symptom burden. 

References:

  1. Aaron SD, Vandemheen KL, FitzGerald JM, Ainslie M, Gupta S, Lemière C, Field SK, McIvor RA, Hernandez P, Mayers I, Mulpuru S. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA. 2017;317(3):269-79.
  2. National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245) [Internet]. London: NICE; 2024 [cited 2026 18 Jun]. Available from: https://www.nice.org.uk/guidance/ng245
  3. Patel S, Huang M, Miliara S. Understanding treatment adherence in chronic diseases: challenges, consequences, and strategies for improvement. Journal of Clinical Medicine. 2025 Aug;14(17):6034. DOI: 10.3390/jcm14176034.
  4. Canonica GW, Domingo C, Lavoie KL, Kaliasethi A, Khan SQ, Majumdar A, Fulmali S. Asthma patients’ and physicians’ perspectives on the burden and management of asthma: post-hoc analysis of APPaRENT 1 and 2 to assess predictors of treatment adherence. Respiratory medicine. 2024;227:107637.
  5. Bosnic-Anticevich S, Bender BG, Shuler MT, Hess M, Kocks JW. Recognizing and tackling inhaler technique decay in asthma and chronic obstructive pulmonary disesase (COPD) clinical practice. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(8):2355-64.

Almost 10 months after the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN) released an updated joint guideline for asthma care and management, a major milestone has been hit. Over 1 million people are now using combination inhalers instead of relying solely on blue reliever inhalers, marking a major shift towards inflammation-focused asthma management.1

Why does this matter?

Previously, many people living with asthma relied on their blue reliever inhaler, which relieved symptoms, making them feel better quickly. The problem with this was that whilst symptoms were being addressed, the underlying airway inflammation, the main driver of their symptoms, was not being treated. If the inflammation is not treated, symptoms continue to recur, damaging quality of life and increasing over-reliance on medication.1

The problem with symptom-led asthma care.

Patients who rely heavily on Short-Acting Beta-Agonist (SABA) inhalers (rescue inhalers) may report feeling well and believe that their asthma is well controlled because regular use of their inhaler keeps their symptoms at bay.1 When, in reality, this reliance is masking the underlying issue: airway inflammation.

Combination Asthma Inhaler - FeNO and modern asthma care
Airway Inflammation Infographic

Airway inflammation cannot always be felt, and if left untreated, it could lead to further exacerbations, including asthma attacks.

The shift towards prevention-focused care.2

The update to the guideline placed greater emphasis on treating the underlying inflammation rather than just the symptoms, demonstrating an evolution in asthma care. The updated guidance reflects:

  • Earlier anti-inflammatory treatment,
  • Reduced SABA reliance,
  • Prevention of exacerbations,
  • More proactive asthma management.

The impact of this guidance is clear: over 1 million people now use combination inhalers to relieve symptoms and treat underlying inflammation, a significant milestone for asthma care.1

Why objective insight matters.

During routine asthma reviews, patients are typically asked about their symptoms, which rely on patient recall. Typically, people with asthma downplay their symptoms, believing that what they experience is typical of their condition.3

And whilst peak flow remains a useful tool in asthma care, it alone may not provide the full picture. It measures airflow obstruction, rather than the inflammatory activity driving asthma, demonstrating the need for objective assessment, because better asthma care starts with better insight.

The role of FeNO testing.2

Fractional exhaled Nitric Oxide (FeNO) testing provides an objective tool to measure airway inflammation. It is non-invasive, easy to do at the point of care and supports:

  • Diagnosis,
  • Inhaled corticosteroid (ICS) decisions,
  • Adherence assessment,
  • Monitoring,
  • Evaluation of exacerbation risk.

Aligning with the latest guidance, FeNO supports the move towards more personalised, biomarker-driven asthma care.

The NObreath® FeNO device.

The NObreath® is a modern FeNO device; it is portable and easy to use, making it perfect for primary care. Clinicians can measure a person’s airway inflammation in a short amount of time, fitting perfectly into a standard healthcare appointment. This objective insight enables clinicians to make informed decisions there and then without the need for a follow-up appointment to discuss results.

Combined with an extensive clinical history, a FeNO test with the NObreath® can aid in an asthma diagnosis and tailor treatment appropriately, providing enhanced asthma monitoring.

Precision medicine and the future of asthma care.2

Guidelines are updated as technology and research evolve to improve patient care. The latest guideline from NICE/BTS/SIGN marked a move towards:

Taking a FeNO test with the NObreath
  • Precision medicine,
  • Biomarkers
  • Personalised pathways
  • Earlier intervention,
  • Better outcomes.

The move towards combination inhalers marks more than a treatment change; it represents a broader evolution in how asthma is understood and managed. Objective insight can provide clinicians with a better understanding of what is going on beneath the surface, with FeNO testing supporting this objective insight and supporting future asthma care.

As asthma care continues to evolve, understanding airway inflammation will become increasingly important in helping clinicians deliver a more personalised and proactive approach.

To learn more about the NObreath® device and how FeNO testing is improving patient outcomes worldwide, visit the website here.

References

  1. “I no longer feel asthmatic”: more than a million people now using new style inhalers [Internet]. NICE website: The National Institute for Health and Care Excellence. NICE; 2026. Available from: https://www.nice.org.uk/news/articles/-i-no-longer-feel-asthmatic-more-than-a-million-people-now-using-new-style-inhalers
  2. National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024. Available from: https://www.nice.org.uk/guidance/NG245
  3. Bidad N, Barnes N, Griffiths C, Horne R. Understanding patients’ perceptions of asthma control: a qualitative study. European Respiratory Journal. 2018 May 17;51(6):1701346.

Demonstrating innovations in respiratory and allergy diagnostics with the NObreath® and Gastrolyzer® range.

Bedfont® Scientific Ltd., an innovative leader in the medical breath analysis industry with almost 50 years of experience, is pleased to join thousands of healthcare experts at this year’s European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026 at stand I03 to showcase its NObreath® and Gastrolyzer® range of non-invasive breath analysis devices.

The congress, taking place in Istanbul, Türkiye from Friday 12th to Sunday 14th of June, is widely recognised as the world’s largest and most influential meeting dedicated to allergy and clinical immunology. It brings together thousands of clinicians, researchers and healthcare professionals from across the globe each year to share new ideas and showcase innovations in diagnostics, playing a central role in advancing research, education and patient care in allergic diseases such as asthma and food allergy.

“Attending the EAACI Congress 2026 reflects our commitment to strengthening our global network. We look forward to connecting with like-minded organisations, sharing insights into our technology, and exploring new distribution partnerships with those seeking innovative solutions.” Said Jason Smith, CEO at Bedfont®. “We see EAACI as a key opportunity to build relationships that will drive future growth in the allergy and immunology space.”

The Bedfont® team is pleased to be joined by its Turkish distributor, Teknikel, to demonstrate its Fractional exhaled Nitric Oxide (FeNO) and hydrogen and methane breath testing (HMBT) technologies, highlighting how these innovative tools can support improved diagnosis, monitoring, and the management of respiratory and gastrointestinal conditions.

The team will be at stand I03, where you can find the NObreath® FeNO device, which has been improving asthma care and management for over 15 years, providing an objective insight into airway inflammation, a key driver of asthma symptoms. And the Gastrolyzer® range of HMBT devices, which have been aiding gastrointestinal investigation for over 35 years, enabling clinicians to tailor treatment effectively.

For Bedfont®, this congress is invaluable not only for showcasing its solutions but also for engaging with partners and stakeholders as it continues to advance technology and expand its global reach. To learn more, visit the website here.

Bedfont® Team at EAACI 2025

Bedfont® Scientific Limited to showcase why the NObreath® is the FeNO device of choice at this year’s global event.

World leaders in breath analysis Bedfont® Scientific Ltd. are pleased to be attending this years American Thoracic Society (ATS) International Conference, to exhibit the innovative NObreath® Fractional exhaled Nitric Oxide (FeNO) device at booth 1236 alongside its US distributor coVita™. Bedfont® is an innovative MedTech company with nearly 50 years of expertise in the design and manufacture of medical breath analysis devices, helping to improve patient outcomes worldwide.

The ATS International Conference, taking place from the 15th and 20th May at the Orange County Convention Centre in Orlando, Florida, is a global event attracting more than 15,000 experts in pulmonary, critical care and sleep medicine to share groundbreaking research and advance clinical practice. Bedfont® will be sharing how the NObreath® is revolutionising asthma care worldwide.

The team can be found at booth 1236, where they will showcase the NObreath®, which has been helping to improve asthma care and management for over 15 years by providing objective insight into airway inflammation, a key feature of asthma. It enables clinicians to measure inflammation non-invasively, supporting a future where today’s science meets tomorrow’s care.

“We’re excited to be part of ATS this year and to bring our expert team together on the stand to engage with the global respiratory community. We invite attendees to come and speak with us, experience our technology firsthand, and explore how we can work together.” Said Jason Smith, CEO at Bedfont®. “ATS provides an important platform for us to showcase the NObreath® and its impact in respiratory care.” 

Bedfont team at ATS 2025

Joining Bedfont® and coVita™ at booth 1236 is Medical Advisory Board Member, Carol Stonham MBE, a respiratory expert who serves as the Children and Young People Asthma Clinical Lead at Gloucestershire ICB. Carol will be bringing a wealth of knowledge to the event and will be hosting a talk at Innovation Hub 3 on Sunday 17th May at 1:15 pm EDT; where she will explore the role of FeNO in practice and discuss emerging opportunities.

You will find the Bedfont® team at booth 1236 between the 17th and 19th May, to find out more visit the website here.

In 2019, 262 million people worldwide had asthma, with 455,000 deaths from the chronic condition1, stark figures that highlight asthma control still needs improvement. Most people living with asthma believe that no physical symptoms mean their asthma is controlled, but this is sadly not always the case. Airway inflammation is the underlying cause of asthma, something that cannot be seen and not always felt.

Many asthma patients feel fine until they don’t. Objectively measuring airway inflammation with Fractional exhaled Nitric Oxide (FeNO) testing is a vital way to prevent exacerbations and improve overall asthma care.

Airway Inflammation Infographic - Advancements in FeNO Testing

What is FeNO and why does it matter2?

When airways are inflamed, they produce excess nitric oxide (NO), a gas that can be measured by performing a FeNO test. A FeNO test provides insight into a person’s airway inflammation by measuring NO levels in exhaled breath.

  • High FeNO levels indicate eosinophilic airway inflammation. The higher the reading, the more severe the inflammation is.

By measuring airway inflammation, healthcare professionals can use the results to aid an asthma diagnosis and tailor treatment appropriately.

Limitations of traditional asthma monitoring.

Taking a FeNO test with the NObreath - Advancements in FeNO Testing

Traditionally, clinicians have relied on patients relaying their symptoms, which doesn’t always give the full picture of a person’s asthma. Many people believe that because they have asthma, they should have a cough and they should have a wheeze, and they downplay their symptoms.

Providing a FeNO test at regular asthma reviews empowers healthcare professionals to detect airway inflammation early, allowing them to monitor medication response and personalise treatment. This ultimately can catch an exacerbation early and get patients back on track with well-controlled asthma.

Additionally, medication adherence rates range from 30% to 70%3. A patient may report taking their medication regularly and using the correct technique; however, a quick, easy FeNO test can reveal poor adherence. Showing a patient their airway inflammation can create an opportunity to discuss and reinforce the importance of good adherence and technique.

Recent advancements in FeNO testing.

NObreath device - Advancements in FeNO Testing

In the 1990s, researchers found that FeNO served as a non-invasive biomarker of airway inflammation and used chemiluminescence to measure it. This method proved very costly due to regular maintenance and calibration, and difficult to access because of the machines’ size and the specialist training required.

In recent years, this has advanced to electrochemical sensor technology, enabling more cost-effective, portable FeNO devices like the NObreath®, whilst still matching the gold-standard technology of chemiluminescence. Thanks to continuous innovation, FeNO devices are now accessible at the point of care and provide instant results, improving patient outcomes.

To learn more about chemiluminescence and electrochemical sensor technology, read our article here.

In the late 1990s, FeNO began to appear in international clinical practice guidelines for asthma, and the American Thoracic Society (ATS) officially recommended its use to assess airway inflammation in adults and children in 20114.

Since then, FeNO testing has been recommended in asthma guidelines across the world, with the most recent joint guidance from the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN), recommending FeNO as a first-line test for asthma diagnosis5.

To learn more about the global guidelines on asthma care and management, read our article here.

The NObreath® FeNO device

The NObreath® was developed in 2008, designed with healthcare professionals and patients in mind. It provides a non-invasive, fairly priced option for FeNO testing, making it more accessible to healthcare providers worldwide.

Featuring an adult and child test mode, the NObreath® is suitable for all settings thanks to its accuracy and portability. It requires an exhalation-only manoeuvre, making it a quick and easy test to take for both adults and children.

The device was designed with the patient in mind and features multiple flow incentive screens. These incentive screens not only engage the patient, but they also ensure a correct flow rate of 50 ml/s, providing an accurate test result.

To learn more about FeNO testing with the NObreath®, visit the website here.

Child test with the NObreath - Advancements in FeNO Testing

Many deaths from asthma are thought to be preventable, meaning better asthma care is needed. Advances in FeNO testing have been instrumental in improving asthma control, and with increasing recognition in global asthma guidelines, FeNO testing can make a difference.

To learn more about Bedfont® Scientific Limited, world leaders in breath analysis with over 49 years of expertise in the medical device industry, visit the website here.

References

  1. World Health Organization. Asthma [Internet]. World Health Organization. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma
  2. NHS England. NHS Accelerated Access Collaborative» Fractional Exhaled Nitric Oxide (FeNO) [Internet]. www.england.nhs.uk. 2025. Available from: https://www.england.nhs.uk/aac/what-we-do/innovation-for-healthcare-inequalities-programme/rapid-uptake-products/fractional-exhaled-nitric-oxide/
  3. ‌Improving adherence in Asthma treatment | Cambridge Network [Internet]. Cambridgenetwork.co.uk. 2024. Available from: https://www.cambridgenetwork.co.uk/news/improving-adherence-asthma-treatment
  4. ‌Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. American journal of respiratory and critical care medicine [Internet]. 2011;184(5):602–15. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21885636/
  5. National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024. Available from: https://www.nice.org.uk/guidance/NG245
Back to top